Received: 25 March 2022
Accepted: 27 April 2022
First Online: 8 June 2022
: This study was reviewed and approved by the WIRB-Copernicus Group Independent Review Board (tracking number: 20211304). All participants provided written informed consent prior to the interviews and verbally re-confirmed consent at the start of the interviews.
: Not applicable.
: GL, LH, and VC are employed by and own stock/stock options in Biohaven Pharmaceuticals Inc. SHL, KG, LTH, and EW are employees of Acaster Lloyd Consulting Ltd. AJL is an employee and shareholder of Acaster Lloyd Consulting Ltd. Acaster Lloyd Consulting Ltd were commissioned by Biohaven Pharmaceuticals Inc to conduct the study. TS is an employee of StudyMetrix Research LLC and has received consulting fees from Biohaven Pharmaceuticals Inc in the conduct of this study. LP and KJ are employees of Broadstreet HEOR, which received payment by Biohaven Pharmaceuticals Inc in the conduct of this study.